Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A non-invasive 25-Gene PLNM-Score urine test for detection of prostate cancer pelvic lymph node metastasis.

Prostate cancer and prostatic diseases·2024

Same author

Editorial for the Abstracts of the 20th Meeting of the Association of Academic European Urologists [European Urology Open Science 2023;48(Suppl 1):S1-48].

European urology open science·2023

Same author

Non-invasive Urine Test for Molecular Classification of Clinical Significance in Newly Diagnosed Prostate Cancer Patients.

Frontiers in medicine·2021

Same author

A 23-Gene Classifier urine test for prostate cancer prognosis.

Clinical and translational medicine·2021

Same author

Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up.

BMC medicine·2020

Same author

Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer.

International journal of urology : official journal of the Japanese Urological Association·2020

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Prostate cancer and active surveillance.

Per-Anders Abrahamsson¹

¹Department of Urology, Malmö University Hospital, Malmö , Sweden.

Frontiers of Radiation Therapy and Oncology

|June 12, 2008

Summary

Active surveillance is a suitable option for localized prostate cancer patients with low-volume, well-differentiated tumors and a life expectancy under 10 years. Higher-grade tumors and longer life expectancy may increase prostate cancer mortality risk with active surveillance.

Area of Science:

Urology
Oncology
Medical Decision-Making

Background:

Localized prostate cancer presents multiple treatment options.
Treatment decisions must integrate patient-specific factors and quality of life considerations.

Purpose of the Study:

To review treatment modalities for localized prostate cancer.
To guide clinical decision-making by incorporating patient values and quality of life.

Main Methods:

Literature review of prostate cancer treatment options.
Analysis of factors influencing treatment choice, including patient values and life expectancy.

Main Results:

Active surveillance is appropriate for well/moderately differentiated, low-volume prostate cancer with <10 years life expectancy.

More Related Videos

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Related Experiment Videos

Last Updated: Jul 4, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Active surveillance may pose excess mortality risk for higher-grade tumors or longer life expectancy.

Conclusions:

Personalized treatment strategies are crucial for localized prostate cancer.
Active surveillance can be a safe and effective option when patient and disease factors align.
Risk stratification is essential for optimizing prostate cancer management.